# Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

> **NCT02491983** · PHASE2 · COMPLETED · sponsor: **MedSIR** · enrollment: 486 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02491983
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2020-01
- **Final completion:** 2020-01
- **Target enrollment:** 486 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02491983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02491983, "Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02491983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*